Flexion Therapeutics (NASDAQ:FLXN) Coverage Initiated at Credit Suisse Group

Share on StockTwits

Credit Suisse Group began coverage on shares of Flexion Therapeutics (NASDAQ:FLXN) in a research report sent to investors on Wednesday, 24/7 WallStreet reports. The firm issued an outperform rating and a $19.00 price objective on the specialty pharmaceutical company’s stock.

Other equities research analysts have also issued research reports about the company. Needham & Company LLC dropped their price target on Flexion Therapeutics from $30.00 to $20.00 and set a buy rating for the company in a research note on Friday, May 8th. Royal Bank of Canada dropped their price target on Flexion Therapeutics from $20.00 to $18.00 and set an outperform rating for the company in a research note on Friday, May 8th. Zacks Investment Research raised Flexion Therapeutics from a hold rating to a buy rating and set a $14.00 price target for the company in a research note on Wednesday, July 8th. Guggenheim assumed coverage on Flexion Therapeutics in a research note on Tuesday, May 26th. They set a buy rating and a $20.00 price target for the company. Finally, BidaskClub lowered Flexion Therapeutics from a buy rating to a hold rating in a research note on Friday, July 10th. Two equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $22.08.

Flexion Therapeutics stock opened at $13.57 on Wednesday. Flexion Therapeutics has a 52 week low of $5.01 and a 52 week high of $22.98. The business has a 50-day simple moving average of $12.64 and a 200 day simple moving average of $12.41. The stock has a market cap of $523.26 million, a price-to-earnings ratio of -3.58 and a beta of 2.10.

Flexion Therapeutics (NASDAQ:FLXN) last posted its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported ($0.95) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.00) by $0.05. Flexion Therapeutics had a negative return on equity of 592.50% and a negative net margin of 175.76%. The business had revenue of $20.13 million during the quarter, compared to analysts’ expectations of $18.45 million. Equities research analysts predict that Flexion Therapeutics will post -2.62 EPS for the current year.

In other Flexion Therapeutics news, CEO Michael D. Clayman purchased 10,256 shares of Flexion Therapeutics stock in a transaction that occurred on Tuesday, May 26th. The shares were bought at an average price of $9.75 per share, for a total transaction of $99,996.00. Following the acquisition, the chief executive officer now directly owns 64,957 shares in the company, valued at $633,330.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 17.03% of the stock is owned by insiders.

A number of large investors have recently made changes to their positions in the stock. Monarch Partners Asset Management LLC increased its holdings in Flexion Therapeutics by 135.8% during the 2nd quarter. Monarch Partners Asset Management LLC now owns 58,710 shares of the specialty pharmaceutical company’s stock valued at $772,000 after purchasing an additional 33,815 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Flexion Therapeutics by 791.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,801 shares of the specialty pharmaceutical company’s stock valued at $129,000 after purchasing an additional 8,702 shares during the period. Dupont Capital Management Corp purchased a new position in Flexion Therapeutics during the 2nd quarter valued at about $567,000. First Trust Advisors LP purchased a new position in shares of Flexion Therapeutics during the 2nd quarter worth approximately $211,000. Finally, Moody National Bank Trust Division purchased a new position in shares of Flexion Therapeutics during the 2nd quarter worth approximately $5,067,000. Institutional investors own 82.19% of the company’s stock.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.

Featured Story: What is the Book Value of a Share?

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

NortonLifeLock  Cut to C at TheStreet
NortonLifeLock Cut to C at TheStreet
$185.08 Million in Sales Expected for Highwoods Properties Inc  This Quarter
$185.08 Million in Sales Expected for Highwoods Properties Inc This Quarter
Northrop Grumman  Upgraded at TheStreet
Northrop Grumman Upgraded at TheStreet
Pacific Mercantile Bancorp  Upgraded at TheStreet
Pacific Mercantile Bancorp Upgraded at TheStreet
Simon Property Group  Downgraded by TheStreet
Simon Property Group Downgraded by TheStreet
Sykes Enterprises  Upgraded at TheStreet
Sykes Enterprises Upgraded at TheStreet


© 2006-2020 Ticker Report